Low birth weight in Papua New Guinea is a killer. Help us research what is causing low birth weight in PNG so that we can stop it.
Victoria’s medical research expertise will be exported to China as part of historic agreements signed with key Chinese provinces.
The agreements between Victoria and the Jiangsu and Sichuan provinces will enable joint ventures in biomedical research, healthcare training programs for Victorian GPs and allied health professionals, and assistance to Jiangsu province to help develop its aged care, primary and community health sectors.
The State Government has identified Victoria’s medical technologies and pharmaceuticals sector as playing a major part in the state’s future economic growth.
State Premier, the Hon Daniel Andrews MP said Victoria’s medical researchers are capable, innovative and leaders in their field.
“These agreements will enable Victoria to work collaboratively with these growing regions to enhance our skills and research opportunities,” Mr Andrews said.
Burnet Institute Deputy Director, Associate Professor David Anderson said he is greatly encouraged by the Premier’s renewed commitment to the Victoria-Jiangsu sister-state relationship.
“Victoria’s long relationship with Jiangsu province was a significant factor in deciding the location of Burnet Institute’s first overseas commercial spin-off company, Nanjing BioPoint, and the new agreement with Jiangsu further validates that decision,” he said.
Burnet was the first Australian medical research institute to establish a commercial biotech company in China.
“We recognised the enormous opportunities possible through combining Victoria’s strengths in biomedical research with the investment, technical and manufacturing capacity of Jiangsu,” Associate Professor Anderson explained.
Nanjing BioPoint Diagnostics Technology Co. Ltd. was established to translate the Institute’s world-renowned diagnostic research and technologies into commercially viable products for manufacture and sale worldwide.